Suppr超能文献

长期使用苯二氮䓬类药物治疗会引发桥连蛋白支架不稳定和γ-氨基丁酸A型受体(GABAR)突触下重组。

Chronic benzodiazepine treatment triggers gephyrin scaffold destabilization and GABAR subsynaptic reorganization.

作者信息

Chapman Caitlyn A, Povysheva Nadya, Tarr Tyler B, Nuwer Jessica L, Meriney Stephen D, Johnson Jon W, Jacob Tija C

机构信息

Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA, United States.

出版信息

Front Cell Neurosci. 2025 Jul 4;19:1624813. doi: 10.3389/fncel.2025.1624813. eCollection 2025.

Abstract

Benzodiazepines (BZDs) are important clinical drugs with anxiolytic, anticonvulsant, and sedative effects mediated by potentiation of inhibitory GABA type A receptors (GABARs). Tolerance limits the clinical utility of BZDs, yet the mechanisms underlying tolerance after chronic exposure have not been thoroughly investigated. Here, we assessed the impact of chronic (7-day) treatment with the BZD diazepam (DZP) on the dynamic plasticity and subsynaptic organization of the gephyrin scaffold and γ2 subunit-containing GABARs in primary neurons. After functional confirmation of diminished BZD sensitivity, we provide the first super-resolution analysis of inhibitory nanoscale plasticity induced by chronic BZD exposure: gephyrin subsynaptic domains were smaller and the inhibitory postsynaptic area was overall diminished by DZP treatment, resulting in a condensation of synaptic γ2-GABARs into smaller synaptic areas. Using a novel fluorescence-based proximity ligation assay and biochemical fractionation analysis, the mechanism for gephyrin downregulation was revealed to be dependent on phosphorylation and protease cleavage. Accordingly, DZP treatment impaired gephyrin synaptic stability, demonstrated by live-imaging photobleaching experiments. Despite the loss of BZD sensitivity and stable synaptic gephyrin, 7-day DZP treatment did not reduce the surface or total protein levels of BZD-sensitive γ2-GABARs, as shown in prior short-term BZD treatment studies. Instead, chronic DZP treatment induced an accumulation of γ2-GABARs in the extrasynaptic membrane. Surprisingly, γ2-GABAR interactions with gephyrin were also enriched extrasynaptically. An identified rise in extrasynaptically-localized gephyrin cleavage fragments may function to confine receptors away from the synapse, as supported by a decrease in extrasynaptic γ2-GABAR mobility. Altogether, we find that chronic BZD treatment triggers several subtle converging plasticity events at inhibitory synapses which effectively restrict the synaptic renewal of BZD-sensitive GABARs via mechanisms distinct from those observed with short-term treatment.

摘要

苯二氮䓬类药物(BZDs)是重要的临床药物,具有抗焦虑、抗惊厥和镇静作用,其作用通过增强抑制性γ-氨基丁酸A型受体(GABARs)介导。耐受性限制了BZDs的临床应用,但慢性暴露后耐受性的潜在机制尚未得到充分研究。在此,我们评估了用苯二氮䓬类药物地西泮(DZP)进行慢性(7天)治疗对原代神经元中桥连蛋白支架和含γ2亚基的GABARs的动态可塑性和突触下组织的影响。在功能确认BZD敏感性降低后,我们首次对慢性BZD暴露诱导的抑制性纳米级可塑性进行了超分辨率分析:桥连蛋白突触下结构域变小,DZP处理使抑制性突触后面积总体减小,导致突触γ2-GABARs聚集到更小的突触区域。使用基于荧光的新型邻近连接分析和生化分级分析,发现桥连蛋白下调的机制依赖于磷酸化和蛋白酶切割。相应地,DZP处理损害了桥连蛋白的突触稳定性,实时成像光漂白实验证明了这一点。尽管失去了BZD敏感性和稳定的突触桥连蛋白,但如先前短期BZD治疗研究所示,7天的DZP治疗并未降低BZD敏感的γ2-GABARs的表面或总蛋白水平。相反,慢性DZP治疗导致γ2-GABARs在突触外膜积聚。令人惊讶的是,γ2-GABARs与桥连蛋白的相互作用在突触外也有所富集。已确定的突触外定位的桥连蛋白切割片段的增加可能起到将受体限制在突触之外的作用,突触外γ2-GABARs流动性的降低支持了这一点。总之,我们发现慢性BZD治疗在抑制性突触处引发了几个微妙的汇聚可塑性事件,这些事件通过与短期治疗不同的机制有效地限制了BZD敏感GABARs的突触更新。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5275/12271172/3679dc6ff132/fncel-19-1624813-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验